Pluri announces expansion of manufacturing agreement with Remedy Cell

Pluri (PLUR) announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell. Under the ongoing collaboration Remedy Cell’s personnel, along with Pluri’s Contract Development and Manufacturing Organization division, have successfully completed the full implementation of Remedy Cell’s proprietary manufacturing process into Pluri’s Good Manufacturing Practice, GMP, facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell’s lead candidate. These batches are intended for use in Remedy Cell’s initial Phase 1b clinical trial, representing a major step in its clinical development